<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Calcipotriol (calcipotriene): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Calcipotriol (calcipotriene): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Calcipotriol (calcipotriene): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11622" href="/d/html/11622.html" rel="external">see "Calcipotriol (calcipotriene): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="121841" href="/d/html/121841.html" rel="external">see "Calcipotriol (calcipotriene): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F144061"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Calcitrene;</li>
<li>Dovonex [DSC];</li>
<li>Sorilux</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866163"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Dovonex</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F144076"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Topical Skin Product;</li>
<li>
                        Vitamin D Analog</li></ul></div>
<div class="block doa drugH1Div" id="F144062"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4fb8c5f3-a1b3-4ba3-b517-cc8663ef3c7c">Plaque psoriasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plaque psoriasis:</b>
<b>Topical:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Cream: Apply a thin film to the affected skin twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Foam: Apply a thin film to the affected skin or scalp twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Ointment: Apply a thin film to the affected skin once or twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Solution: Apply to the affected scalp twice daily.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992053"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50989375"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F144063"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; use with caution.</p></div>
<div class="block dop drugH1Div" id="F53346367"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="121841" href="/d/html/121841.html" rel="external">see "Calcipotriol (calcipotriene): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbaaec5b-44c3-4e28-bb8c-cfaf1a9cccd7">Plaque psoriasis, mild to moderate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plaque psoriasis, mild to moderate: Note: </b>Vitamin D analogs (eg, calcipotriene) are recommended treatment options in pediatric patients (particularly to minimize corticosteroid exposure) with or without topical corticosteroids (AAD [Menter 2020]; de Jager 2010; Zeichner 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">Foam: Sorilux: Children ≥4 years and Adolescents: Topical: Apply a thin layer to affected areas of scalp and body twice daily (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">Cream, ointment: Limited data available: Children ≥2 years and Adolescents: Topical: Apply a thin layer to affected areas of scalp and body twice daily; ointment dosing based on multicenter trials including over 100 children ≥2 years of age and adolescents with mild to moderate psoriasis covering &lt;30% BSA; significant improvement (based on psoriasis scores) was reported in over 60% of patients in an open-labeled trial; similar efficacy (&gt;50% improvement) was reported in a placebo-controlled study; however, this was not statistically significant (Darley 1996; Oranje 1997); cream dosing based on a small trial, experience with ointment formulation, and expert recommendations (AAD [Menter 2009]; Duweb 2003; Schachner 2011; Zeichner 2010).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F53346368"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F53346369"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F144048"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Burning sensation of skin (≤23%), pruritus (1% to 15%; including application-site pruritus), skin irritation (1% to 15%), skin rash (1% to 11%), stinging of the skin (≤23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Tingling of skin (≤23%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis, desquamation, erythema of skin, exacerbation of psoriasis (including facial/scalp psoriasis), xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site erythema (2%), application-site pain (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Folliculitis, hyperpigmentation, skin atrophy</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercalcemia</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Local: Application-site pruritus</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic contact dermatitis, contact dermatitis, dyschromia (at application site), exfoliation of skin, skin photosensitivity, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site vesicles</p></div>
<div class="block coi drugH1Div" id="F144057"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to calcipotriene or any component of the formulation; patients with demonstrated hypercalcemia or evidence of vitamin D toxicity; use on the face (cream, ointment); patients with acute psoriatic eruptions (scalp solution).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Ophthalmic use; known disorders of calcium metabolism; pregnancy.</p></div>
<div class="block war drugH1Div" id="F144045"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Contact dermatitis: Contact dermatitis, including allergic contact dermatitis, may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypercalcemia: May cause transient increases in serum calcium (reversible); if hypercalcemia occurs, discontinue treatment until calcium levels return to normal.</p>
<p style="text-indent:-2em;margin-left:4em;">• Irritation: Transient irritation of both lesions and surrounding uninvolved skin may occur; discontinue use if irritation occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in elderly patients; severity of skin-related adverse reactions may be increased compared to younger adults.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Children may be at higher risk of systemic side effects due to a greater skin surface area:body weight ratio. In an off-label trial of pediatric patients (2 to 14 years of age) with psoriasis affecting &lt;30% BSA, no serious adverse effects (including calcium or bone metabolism changed) were observed with calcipotriene ointment application for 8 weeks of therapy (Oranje 1997). With foam application in older pediatric patients (5 to &lt;17 years of age), pharmacokinetic studies have not shown significant evidence of systemic calcipotriene absorption or any effects on indices of calcium metabolism.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Foam, solution: Flammable; keep the foam and the solution away from fire, flame, or smoking during and immediately following application.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP ["Inactive" 1997]; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For external use only; not for ophthalmic, oral, or intravaginal use. Avoid or limit excessive exposure to natural or artificial sunlight, or phototherapy. Thoroughly wash hands after use. The safety and effectiveness in dermatoses other than psoriasis have not been established.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F53346366"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities, which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults, including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F144054"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dovonex: 0.005% (60 g [DSC], 120 g [DSC]) [contains cetearyl alcohol, disodium edta]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.005% (60 g, 120 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Foam, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sorilux: 0.005% (60 g [DSC], 120 g) [contains cetyl alcohol, edetate (edta) disodium, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.005% (60 g [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Calcitrene: 0.005% (60 g) [contains disodium edta, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.005% (60 g, 120 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.005% (60 mL)</p></div>
<div class="block geq drugH1Div" id="F144041"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F144058"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Calcipotriene External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.005% (per gram): $7.06 - $10.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Foam</b> (Sorilux External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.005% (per gram): $16.95</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Calcipotriene External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.005% (per gram): $6.03 - $6.88</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Calcitrene External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.005% (per gram): $6.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Calcipotriene External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.005% (per mL): $5.39 - $5.66</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866164"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dovonex: 0.005% (30 g, 120 g) [contains disodium edta, propylene glycol]</p></div>
<div class="block adm drugH1Div" id="F639165"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Topical:</b> For external use only. Avoid contact with face and eyes (rinse thoroughly with water if contact occurs).</p>
<p style="text-indent:-2em;margin-left:2em;">Cream, foam, ointment: Apply to affected skin; rub in gently and completely. Wash hands thoroughly after use.</p>
<p style="text-indent:-2em;margin-left:2em;">Foam, solution (scalp psoriasis): Prior to using, comb hair to remove debris; apply only to scalp lesions. Rub in gently and completely. Wash hands thoroughly after use. Foam should be applied when hair is dry.</p>
<p style="text-indent:-2em;margin-left:2em;">If the use of multiple topical agents is necessary, apply the various agents at separate times throughout the day (AAD/NPF [Elmets 2021]).</p></div>
<div class="block admp drugH1Div" id="F53346370"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Topical: For external use only. Avoid contact with face and eyes (rinse thoroughly with water if contact occurs). If the use of multiple topical agents is necessary, consider application of the various agents at separate times throughout the day; calcipotriene may be inactivated by acidic topical agents (eg, salicylic acid, lactic acid, hydrocortisone valerate preparations) (AAD [Menter 2009]; Zeichner 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">Cream, foam, ointment: Apply to affected skin; rub in gently and completely. Wash hands thoroughly after use, unless hands are the site being treated. For scalp psoriasis, foam should be applied when hair is dry; prior to using, comb hair to remove debris.</p></div>
<div class="block use drugH1Div" id="F144055"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Plaque psoriasis:</b> Treatment of plaque psoriasis of the body (cream, ointment) or of the scalp (solution) in adults; treatment of plaque psoriasis of the body or of the scalp in patients ≥4 years of age (foam).</p></div>
<div class="block cyt drugH1Div" id="F13298926"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F144049"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Topical): May diminish the therapeutic effect of Calcipotriene. Management: Monitor for reduced calcipotriene efficacy if combined with hydrocortisone valerate. Consider separating the administration of these agents by 10 to 12 hours to minimize the risk of this potential interaction.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactic Acid: May diminish the therapeutic effect of Calcipotriene. Management: Monitor for reduced calcipotriene efficacy if combined with lactic acid. Consider separating the administration of these agents by 10 to 12 hours to minimize the risk of this potential interaction.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylic Acid: May diminish the therapeutic effect of Calcipotriene. Management: Monitor for reduced calcipotriene efficacy if combined with salicylic acid. Consider separating the administration of these agents by 10 to 12 hours to minimize the risk of this potential interaction.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F5633323"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Topical agents are recommended for the treatment of psoriasis in pregnancy; however, agents other than calcipotriene are preferred. When alternatives are not appropriate, limit use to smallest possible area (AAD-NPF [Elmets 2021]; Maul 2021; Simionescu 2021).</p></div>
<div class="block brc drugH1Div" id="F20608816"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if calcipotriene is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Because the risk of significant systemic absorption is limited, breastfeeding is considered compatible with maternal therapy (Butler 2014).</p></div>
<div class="block mop drugH1Div" id="F2841592"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum calcium</p></div>
<div class="block pha drugH1Div" id="F144044"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Synthetic vitamin D<sub>3</sub> analog which regulates skin cell production and proliferation. Binds to vitamin D receptors and inhibits keratinocyte proliferation and enhances keratinocyte differentiation (AAD/NPF [Elmets 2021]).</p></div>
<div class="block phk drugH1Div" id="F639161"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Improvement begins after 2 weeks; marked improvement seen after 8 weeks</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: When applied to psoriasis plaques: Cream, foam: Undetermined; Ointment: ~6%; Solution: &lt;1% </p>
<p style="text-indent:0em;">Metabolism: Absorbed calcipotriene is converted to inactive metabolites</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5383708"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cutanit | Daivonex | Dermocal</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Calcipotriol sandoz | Psorcutan</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Daivonex | Dyvon | Planex</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Calcipotriol sandoz | Daivonex</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Daivonex | Psorcutan</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Calcipotriol 1 A pharma | Calcipotriol 1A Pharma | Calcipotriol hexal | Calcipotriol sandoz | Daivonex | Psorcutan</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cutanit | Daivonex</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Calcipoheal | Calciprol | Daivonex | Dovoborg | Psoritop | Velgarol</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Calcipotriol sandoz | Daivonex</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Dovonex</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cipocal | Dovonex</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Cipotriol | Daivonex</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Daivonex | Psorcutan</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Calcil | Dovonex</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Calpsor | Daivonex | Heximar | Pasitrex | Sorfil | Sorifix solo | Soristop</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Calcipotriolo Sandoz | Daivonex | Psorcutan</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Dovonex | Dovonex fujisawa</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Daivonex | Dipsotrex</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Daivonex | Diobetry a</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Calcipotriol hexal | Daivonex</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Daivonex | Eukadar</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cera nex | Daivonex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Calcipotriol sandoz | Daivonex | Dovonex</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Calcipotriol sandoz | Daivonex</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Daivonex | Dipsotrex</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Bio calci | Cipot | Daivonex | Derma d | Dervit | Potrinex | Sfonex | Soriodan | Treclin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Daivonex | Psorcutan | Sorel | Sorel plus</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Calcipotriene | Calcitrene | Dovonex | Trionex</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Daivonex | Daivonex Scalp</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Daivonex | Glenriaz | Psorcutan</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Calcipotriol sandoz | Daivonex</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Daivonex | Sorel</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Daivonex | Psorcutan</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Psorcutan</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Calponex | Calskin | Daivonex</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Psorcutan</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Daivonex</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Dovonex</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Cipocal</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcipotriol-calcipotriene-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.e1-417.e10; quiz 427. doi: 10.1016/j.jaad.2013.09.009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcipotriol-calcipotriene-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Calcipotriene foam [prescribing information]. San Antonio, TX: Trifluent Pharma LLC; August 2020.</div>
</li>
<li>
<div class="reference">
                  Calcipotriene topical solution [prescribing information]. South Plainfield, NJ: Cosette Pharmaceuticals Inc; November 2019.</div>
</li>
<li>
<div class="reference">
                  Calcitrene ointment (calcipotriene) [prescribing information]. Hawthorne, NY: Taro Pharmaceuticals; November 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8949431">
<a name="8949431"></a>Darley CR, Cunliffe WJ, Green CM, Hutchinson PE, Klaber MR, Downes N. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. <i>Br J Dermatol</i>. 1996;135(3):390-393.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcipotriol-calcipotriene-drug-information/abstract-text/8949431/pubmed" id="8949431" target="_blank">8949431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19900732">
<a name="19900732"></a>de Jager ME, de Jong EM, van de Kerkhof PC, Seyger MM. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. <i>J Am Acad Dermatol</i>. 2010;62(6):1013-1030. doi: 10.1016/j.jaad.2009.06.048.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcipotriol-calcipotriene-drug-information/abstract-text/19900732/pubmed" id="19900732" target="_blank">19900732</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Dovonex (calcipotriene) cream [prescribing information]. Madison, NJ: Leo Pharma; June 2017.</div>
</li>
<li>
<div class="reference">
                  Dovonex (calcipotriene) cream [prescribing information]. Madison, NJ: Leo Pharma; June 2021.</div>
</li>
<li>
<div class="reference">
                  Dovonex (calcipotriene) ointment [prescribing information]. Parsippany, NJ: Leo Pharma; March 2015.</div>
</li>
<li>
<div class="reference">
                  Dovonex (calcipotriene) ointment [product monograph]. Thornhill, Ontario, Canada: LEO Pharma Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15018018">
<a name="15018018"></a>Duweb G, Aldebani S, Elzorghany A, Benghazil M, Alhaddar J. Calcipotriol ointment versus cream in psoriasis vulgaris. <i>Int J Clin Pharmacol Res</i>. 2003;23(2-3):47-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcipotriol-calcipotriene-drug-information/abstract-text/15018018/pubmed" id="15018018" target="_blank">15018018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32738429">
<a name="32738429"></a>Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. <i>J Am Acad Dermatol</i>. 2021;84(2):432-470. doi:10.1016/j.jaad.2020.07.087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcipotriol-calcipotriene-drug-information/abstract-text/32738429/pubmed" id="32738429" target="_blank">32738429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33406520">
<a name="33406520"></a>Maul JT, Anzengruber F, Conrad C, et al. Topical treatment of psoriasis vulgaris: the Swiss treatment pathway. <i>Dermatology</i>. 2021;237(2):166-178. doi:10.1159/000512930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcipotriol-calcipotriene-drug-information/abstract-text/33406520/pubmed" id="33406520" target="_blank">33406520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31703821">
<a name="31703821"></a>Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. <i>J Am Acad Dermatol</i>. 2020;82(1):161-201. doi:10.1016/j.jaad.2019.08.049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcipotriol-calcipotriene-drug-information/abstract-text/31703821/pubmed" id="31703821" target="_blank">31703821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19217694">
<a name="19217694"></a>Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. <i>J Am Acad Dermatol</i>. 2009;60(4):643-659. doi:10.1016/j.jaad.2008.12.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcipotriol-calcipotriene-drug-information/abstract-text/19217694/pubmed" id="19217694" target="_blank">19217694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9039169">
<a name="9039169"></a>Oranje AP, Marcoux D, Svensson A, et al. Topical calcipotriol in childhood psoriasis. <i>J Am Acad Dermatol</i>. 1997;36(2):203-208.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcipotriol-calcipotriene-drug-information/abstract-text/9039169/pubmed" id="9039169" target="_blank">9039169</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Schachner L, Hansen R, eds. <i>Pediatric Dermatology</i>. 4th ed. Philadelphia, PA: Mosby Elsevier; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcipotriol-calcipotriene-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34441010">
<a name="34441010"></a>Simionescu AA, Danciu BM, Stanescu AMA. State-of-the-art review of pregnancy-related psoriasis. <i>Medicina (Kaunas)</i>. 2021;57(8):804. doi:10.3390/medicina57080804<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcipotriol-calcipotriene-drug-information/abstract-text/34441010/pubmed" id="34441010" target="_blank">34441010</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sorilux (calcipotriene) [prescribing information]. Greenville, NC: Mayne Pharma; May 2019.</div>
</li>
<li>
<div class="reference">
                  Sorilux foam (calcipotriene) [prescribing information]. Greenville, NC: Mayne Pharma; November 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcipotriol-calcipotriene-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21049712">
<a name="21049712"></a>Zeichner JA, Lebwohl MG, Menter A, et al; Psoriasis Process of Care Consensus Panel. Optimizing topical therapies for treating psoriasis: a consensus conference. <i>Cutis</i>. 2010;86(3 Suppl):5-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcipotriol-calcipotriene-drug-information/abstract-text/21049712/pubmed" id="21049712" target="_blank">21049712</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9181 Version 252.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
